Abstract: The invention provides a method of identifying nucleic acid molecules that contain cis acting nucleic acid elements. Also provided is a method of isolating nucleic acid binding factors. The invention also provides methods of identifying compounds that are cis acting nucleic acid element analogs, compounds that are nucleic acid binding factor analogs, compounds that selectively bind cis acting nucleic acid elements and compounds that selectively displace binding between a nucleic acid binding factor and a cis acting nucleic acid element or between nucleic acid binding factors. Also provided is a method of determining a binding state of a nucleic acid. Pluralities of isolated nucleic acid molecules containing cis acting nucleic acid elements, of isolated cis acting nucleic acid elements and of isolated nucleic acid binding factors are also provided.

Abstract: Methods for screening pigs to determine which are more likely to produce larger litters and/or are less likely to produce larger litters are provided, based on identification of OPN alleles present in a sample of pig genomic DNA. Kits for use in such methods are also provided.

Abstract: Foam precursor materials are taught comprising an epoxy resin having an epoxy equivalents value of about 300-4000, a curing agent and a foaming agent. The foam precursor materials may be expanded and cured by heat to form foam materials that exhibit excellent rigidity. The resulting foam materials may have a compression strength of about 200-2000 Kgf and a density of about 0.20 to 0.40 grams per cubic centimeter.

Abstract: Novel benzimidazole compounds of the following structure and their use as fructose-1,6-bisphosphatase inhibitors is described

Abstract: An apparatus and method for producing tissue slides is disclosed. The apparatus includes a holding assembly for manipulating the sample block, a blade assembly for preparing a thin section from the sample block, and a transfer roller mechanism for transferring the thin section to a receiving medium. The apparatus further includes a controller that may track the sample block and thin section. The method includes the steps of first locating a sample embedded within a support medium, which may be paraffin or a similar medium. Next, the embedded sample is oriented in such a way that its working surface is presented. This orientation may entail determining the orientation of the embedded sample with respect to the blade that will produce the largest cross-sectional area. Next, a slice of the sample from said embedded sample is removed and subsequently transferred to a suitable receiving medium, which may include a microscope slide.

Abstract: This invention provides a particulate material suitable for use as a nutritional supplement, particularly as an aquaculture feed. The particulate material has a high proportion of DHA residues in the lipid fraction, which may be up to 35% of the material, or even more. Preferably, the material has a mean particle size of from about 5 microns to about 10 microns. This invention also provides a method for preparing a particulate material suitable for use as an aquaculture feed from microbial biomass, preferably from algal cells having a high content of DHA residues, by obtaining a lipid fraction from the biomass, preferably by solvent extraction of broken cells, followed by separating a fraction containing phospholipids and proteins from the lipid fraction, and removing water from the protein/phospholipid fraction to form a low moisture particulate, preferably by spray-drying the protein/phospholipid fraction.

Abstract: The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about six-to-one (6:1), more preferably a range of about three-to-two (3:2) to about four-to-one (4:1), and most preferably about two-to-one (2:1), by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release guaifenesin tablet which has two portion: the first portion comprises an immediate release formulation of guaifenesin and the second portion comprises a sustained release formulation of guaifenesin as described above.

Abstract: This invention relates to a lateral flow immunochromatographic assay device without a plastic housing. The assay includes a sample receiving region, analyte detection region and end region all made of porous material and capable of lateral flow. The analyte detection region includes labeling reagents, a capture reagent and a control reagent. The back of the porous material is laminated with a semi-rigid material with adequate mechanical strength. The top is partially covered with a thin plastic material so as to leave a portion of the sample receiving region exposed for sample application.

Abstract: Disclosed are novel metal pterin and pterin analog complexes and compositions useful as antineoplastic and antiviral agents.

Abstract: Shaped foamable structures 10 for filling hollow structural members 1 preferably include a shaped foamable material 11 constructed from a plurality of foamable pieces 12 that are arranged with desired clearances and are interconnected with each other, and a support member 30 for positioning the shaped foamable material 11 within a cavity 6 of the hollow structural member 1. Methods for using the shaped foamable structures 10 include placing the shaped foamable structures 10 within the hollow structural members 1 and heating the foamable material 11 to expand and fill the hollow structural member 1.

Abstract: A multi electrode and needle injection device for identifying and treating muscle pain using two simultaneous electrode EMG recordings to locate an active trigger point. The two electrodes are displaced so that one electrode detects EMG activity at the trigger point and the other detects EMG activity adjacent to the trigger point, within the same muscle. The combination of the electrodes with a drug delivery system allows the user to inject a medication locally at the trigger point to block the trigger point activity and reduce or eliminate muscle pain. The electrodes are on a hypodermic needle. The needle is used to both facilitate the location of the trigger points, and for treatment, by injecting a drug into the trigger points.

Abstract: The present invention relates to a combination of active substances for enhancing the skin's defense against chemical and physical irritations, for example, from job-related stress, strain on the skin from leisure activities (bathing, showering, sun exposure, household chemicals, building materials, etc.) and from the working environment. The topical agent comprises ionically bound and/or free thiocyanate ions and urea in addition to per se known auxiliary agents and carriers.

Abstract: A system for event detection employs a collector that collects raw audit data made up of raw audit data records at an audit source; a database; an inserter at a downstream processing location that inserts Virtual Records into the database, including both a first type of Virtual Record generated in response to a raw audit data record, and a second type of Virtual Record generated in response to a detected audit event; the inserter; a parser; coupled to the collector, that converts raw audit data records in the raw audit data into Virtual Records; a detector that detects audit events in response to the Virtual Records generated by the parser, and generates the second type of Virtual Record in the event an audit event is detected.

Abstract: The present invention pertains to a method for the preparation of putamen ovi, putamen ovi having a defined grain size distribution, and to the use of putamen ovi for the treatment of calcium deficiency and other disease conditions.

Abstract: This invention provides modified phycobilisomes and phycobilisome complexes that are supramolecular complexes with diverse spectral properties, and which may optionally be immobilized on a manufactured solid support. The invention provides a versatile set of highly sensitive signal-generating systems and conjugates that may be used as highly detectable tracers and labels, or in biotransducers comprising phycobilisomes or phycobilisome complexes, and also provides methods for performing specific binding assays using signal-generating systems comprising phycobilisomes as detectable labels. The embodiments of the invention provide the art with an extremely sensitive, nonisotopic detection means for assaying analytes and for sensing molecular events and environmental conditions.

Abstract: The invention refers to an aqueous solution for the parenteral nutrition of mammals consisting of: a) a pattern of amino acids calculated on the basis of 100 g/l of amino acids: Isoleucine 4.0-5.5 g/l Leucine 8.0-10.0 g/l Lysine 6.0-8.0 g/l Methionine 4.0-6.0 g/l Phenylalanine 4.0-6.0 g/l Threonine 4.0-6.0 g/l Tryptophane 1.0-2.0 g/l Valine 6.0-8.0 g/l Arginine 10.0-12.0 g/l Histidine 1.5-3.5 g/l Alanine 9.0-12.0 g/l Aminoacetic Acid (Glycine) 11.0-16.0 g/l Asparagine 0-1.0 g/l Aspartic Acid 5.5-8.0 g/l Acetylcysteine 0-2.5 g/l Glutamic Acid 6.0-10.0 g/l Ornithine 0-1.0 g/l Proline 4.0-6.0 g/l Serine 1.0-3.0 g/l Tyrosine* 01.-0.5 g/l *as Acetyltyrosine 0-2.0 g/l Taurine 0-4.